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72% received disability payments. In the UK, the annual costs of
unemployment and suicide were £1510 million and £179
million, respectively. The estimated UK national cost of bipolar
disorder was €4.59 billion, with hospitalization during acute
episodes representing the largest component. CONCLUSIONS:
Bipolar disorder is a major and underestimated health problem in
Europe. A number of issues impact on the burden of the disease,
such as comorbidities, suicide, early death, unemployment or
underemployment. Direct costs of bipolar disorder are mainly
associated with hospitalization during acute episodes. Indirect
costs are a major contributor to the disease burden but are not
always recognized in research studies. Supported by funding
from AstraZeneca Pharmaceuticals LP.
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OBJECTIVES: While pharmacological hepatic interaction
mechanisms for antipsychotics are largely known, there is little
research so far on the prevalence of potential interactions with
other substances. The objective of the present study is to estimate
the annual prevalence of potential pharmacokinetic drug-drug
interactions (DDIs) between antipsychotic and non-antipsychotic
therapies in patients with schizophrenia. METHODS: A retro-
spective analysis of drug prescriptions for patients treated for
schizophrenia (ICD-10 codes F20–F29) was performed using the
German IMS Disease Analyzer data for psychiatrists for 2007.
These data originate from electronic medical records from a
representative panel of German psychiatrists, and include drug
prescriptions and medical diagnoses. Potential antipsychotic
drug-drug interactions based on cytochrome P450 metabolism
(1A2, 2D6, 3A4, and 3A pathways) for antipsychotics and cor-
responding interacting drugs (pathway inducers and inhibitors)
were identiﬁed based on literature and drug information
resources. A potential DDI was identiﬁed when combinations
known to interact had 20 or more days of overlap, determined by
prescription dates, dosing information and pack size. Incidence
of overlap was calculated by antipsychotic, metabolic pathway
and interaction mechanism. RESULTS: A total of 5449 patients
received an atypical antipsychotic. The most frequent interaction
mechanisms were inhibition of CYP2D6 and of CYP3A4:
between 38% and 45% of the patients treated with atypicals had
a 20 day-overlap with inhibitors of CYP2D6, and 17% to 26%
with CYP3A4-Inhibitors. Potential interactions were most com-
monly associated with antidepressants. CONCLUSIONS: The
risk of potential DDI in schizophrenia patients treated with
antipsychotics in Germany is common, mainly due to concomi-
tant prescription of antipsychotics and antidepressants. The
reported estimates are based on real world data for psychiatrists
in Germany, and are conservative, since drugs prescribed by
other physicians or bought over the counter could not be taken
into account.
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OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as the
outcomes considered by patients taking atypical antipsychotics
to be the most troublesome. This research was designed to
compare the tolerability of the new extended release quetiapine
to the existing quetiapine immediate release formulation on these
outcomes in addition to orthostatic hypotension, which could be
a signiﬁcant cause of morbidity. METHODS: Systematic review
of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with acute bipolar disorder
treated with quetiapine was conducted in May 2008. Meta-
analyses of quetiapine vs placebo used a random effects model.
The results from the individual meta-analyses formed the basis of
an adjusted indirect comparison of the two quetiapine formula-
tions using placebo as a common comparator. Summary effect
estimate for each outcome was calculated as relative risk (RR)
with 95% conﬁdence interval (95% CI) where RR < 1 favoured
extended release and RR > 1 favoured immediate release.
RESULTS: Of the 331 papers initially identiﬁed in the literature
search, 5 RCTs compared quetiapine with placebo with a
common daily dose of 300mg (4 RCTs immediate release and 1
RCT extended release). Adjusted indirect comparison identiﬁed
no signiﬁcant differences between the two formulations of que-
tiapine in the outcomes assessed. Individual results were as
follows: EPS RR0.34 (95% CI: 0.04 to 12.07); orthostatic
hypotension RR1.81 (95% CI: 0.19 to 57.84); prolactin RR1.92
(95%CI: 0.11 to 123.24); sedation RR1.09 (95%CI: 0.51 to
6.29); weight gain RR0.26 (95% CI: 0.05 to 6.86). CONCLU-
SIONS: This adjusted indirect comparison of ﬁve placebo-
controlled clinical trials suggests that the tolerability proﬁle of
extended release quetiapine is consistent with that of the imme-
diate release formulation. Further research will need to be con-
ducted to determine if these results are replicated in real-life
clinical practice.
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OBJECTIVES: To compare the tolerability proﬁles of atypical
antipsychotics assessed in randomised controlled trials (RCTs).
METHODS: Systematic review of BIOSIS, CENTRAL,
EMBASE, MEDLINE, PsycINFO for RCTs comparing two or
more atypical antipsychotics (aripiprazole—ARI, olanzapine—
OLZ, quetiapine—QTP, risperidone—RSD, ziprasidone—ZPD).
Searching was restricted to English-language publications and
was completed in December 2007. Data were extracted on the
following outcomes: anxiety or depression, bodily anxiety or
restlessness, dizziness or nausea, extrapyramidal symptoms
(EPS), sexual dysfunction, stiffness or tremor, tiredness or weak-
ness, weight gain. Data were recalculated if not presented in an
intention-to-treat format. Mixed treatment comparisons were
conducted by Bayesian Markov Chain Monte Carlo simulation
using uninformed priors. Summary effect estimates (Odds Ratios
[OR], 95% credible intervals [95%CrI]) were calculated com-
pared to RSD. RESULTS: Of the 2963 papers identiﬁed in the
literature search, 50 were found to provide data on 48 RCTs
comparing two or more atypical antipsychotics. The results pre-
sented a wide spectrum of tolerability among the atypical antip-
sychotics with no single treatment being identiﬁed as consistently
better tolerated than all other. The outcomes that could be con-
sidered statistically signiﬁcant at the 5% level were: decrease in
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